An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Buntanetap (Primary)
- Indications Mild cognitive impairment
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Annovis Bio
- 21 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 13 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Additional lead trial investigator, planned patient no, official title identified as reported by ClinicalTrials.gov.